Endogenous type-I interferon activity is not associated with depression or fatigue in systemic lupus erythematosus

被引：20
|
作者：
Kellner, Erinn S. [1 ,2 ]
Lee, Pui Y. [1 ,2 ,3 ]
Li, Yi [1 ,2 ]
Switanek, Juliana [1 ,2 ]
Zhuang, Haoyang [1 ,2 ]
Segal, Mark S. [1 ,2 ,3 ]
Sobel, Eric S. [1 ,2 ,4 ]
Satoh, Minoru [1 ,2 ,4 ]
Reeves, Westley H. [1 ,2 ,4 ]
机构：
[1] Univ Florida, Div Rheumatol & Clin Immunol, Gainesville, FL 32610 USA
[2] Univ Florida, Ctr Autoimmune Dis, Gainesville, FL 32610 USA
[3] Univ Florida, Div Nephrol Hypertens & Transplantat, Gainesville, FL 32610 USA
[4] Univ Florida, Dept Pathol Immunol & Lab Med, Gainesville, FL 32610 USA
来源：
JOURNAL OF NEUROIMMUNOLOGY | 2010年 / 223卷 / 1-2期
关键词：
Systemic lupus erythematosus; Depression; Fatigue; Type-I interferon; INDUCIBLE GENE-EXPRESSION; CHRONIC HEPATITIS-C; DISEASE-ACTIVITY; PSYCHIATRIC MANIFESTATIONS; COGNITIVE DYSFUNCTION; IFN-ALPHA; ANTIBODIES; SLE; ACTIVATION; RECEPTORS;
D O I：
10.1016/j.jneuroim.2010.03.018
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Patients with systemic lupus erythematosus (SLE) often suffer from depression and fatigue in addition to the physical manifestations of the autoimmune disease. Elevated production of type-I interferons (IFN-I) has been found in lupus patients and IFN-I can precipitate a variety of neuropsychiatric side effects. This study was conducted to evaluate the relationship between dysregulated IFN-I production and the presence of depression or fatigue in lupus patients. Through cross-sectional and longitudinal analysis we found no significant correlation between abnormal IFN-I levels (as measured by peripheral blood expression of IFN-I-stimulated genes) and neuropsychiatric manifestations. Elevation of endogenous serum IFN-I levels is unlikely to account for the depression and fatigue associated with SLE.
引用
收藏
页码：13 / 19
页数：7
相关论文
共 50 条
  • [41] ANTIBODIES TO THE HUMAN LYMPHOCYTOTROPHIC-T TYPE-I IN SYSTEMIC LUPUS-ERYTHEMATOSUS
    DANAO, T
    REGHETTI, G
    YENLIEBERMAN, B
    STARKEY, C
    WAKASUGI, K
    MCLEANJOHNSON, W
    CLOUGH, J
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 1991, 9 (01) : 55 - 58
  • [42] Comparison of Surrogate Markers of the Type I Interferon Response and Their Ability to Mirror Disease Activity in Systemic Lupus Erythematosus
    Enocsson, Helena
    Wettero, Jonas
    Eloranta, Maija-Leena
    Gullstrand, Birgitta
    Svanberg, Cecilia
    Larsson, Marie
    Bengtsson, Anders A.
    Ronnblom, Lars
    Sjowall, Christopher
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [43] Factors associated with fatigue in patients with systemic lupus erythematosus
    Bruce, IN
    Mak, VC
    Hallett, DC
    Gladman, DD
    Urowitz, MB
    ANNALS OF THE RHEUMATIC DISEASES, 1999, 58 (06) : 379 - 381
  • [44] Type I interferon blockade in systemic lupus erythematosus: where do we stand?
    Lauwerys, Bernard R.
    Ducreux, Julie
    Houssiau, Frederic A.
    RHEUMATOLOGY, 2014, 53 (08) : 1369 - 1376
  • [45] Modulation of Cardiometabolic Disease Markers by Type I Interferon Inhibition in Systemic Lupus Erythematosus
    White, Wendy I.
    Kaplan, Mariana J.
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 (03) : A20 - A20
  • [46] FACTORS ASSOCIATED WITH FATIGUE IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS
    Lisitsyna, T. A.
    Veltishchev, D.
    Gerasimov, A.
    Seravina, O.
    Kovalevskaya, O.
    Marchenko, A.
    Krasnov, V.
    Nasonov, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 187 - 187
  • [47] Type I interferon expression in family members of patients with systemic lupus erythematosus.
    Niewold, Timothy
    Hua, Jing
    Crow, Mary
    CLINICAL IMMUNOLOGY, 2006, 119 : S64 - S64
  • [48] PORTRAIT OF A PATIENT WITH SYSTEMIC LUPUS ERYTHEMATOSUS FOR THE PRESCRIPTION OF THE TYPE I INTERFERON INHIBITOR ANIFROLUMAB
    Issayeva, B.
    Aseeva, E.
    Reshetnyak, T.
    Nikishina, N.
    Issayeva, S.
    Saparbayeva, M.
    Bizhanova, M.
    Amanzholova, A.
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2024, 36 : S539 - S540
  • [49] Type I Interferon Predicts an Alternate Immune System Phenotype in Systemic Lupus Erythematosus
    Thanarajasingam, Uma
    Muppirala, Anoohya N.
    Jensen, Mark A.
    Ghodke-Puranik, Yogita
    Dorschner, Jessica M.
    Vsetecka, Danielle M.
    Amin, Shreyasee
    Makol, Ashima
    Ernste, Floranne
    Osborn, Thomas
    Moder, Kevin
    Chowdhary, Vaidehi
    Niewold, Timothy B.
    ACR OPEN RHEUMATOLOGY, 2019, 1 (08) : 499 - 506
  • [50] Type I interferon-associated cytotoxic inflammation in cutaneous lupus erythematosus
    Joerg Wenzel
    Sabine Zahn
    Thomas Bieber
    Thomas Tüting
    Archives of Dermatological Research, 2009, 301 : 83 - 86
12345